Q-omics provides the consensus-scored NYAP1 profile across patient tissues and cancer cell-line models. NYAP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NYAP1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NYAP1 RNA expression shows 18,322 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where NYAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NYAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NYAP1 survival associations across molecular data types. NYAP1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NYAP1 RNA expression–survival associations across cancer types. High NYAP1 expression shows unfavorable associations in LUAD, UCEC, ACC and COAD, but favorable associations in PAAD and ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify LUAD as the clearest survival context for NYAP1 RNA expression.
This table summarizes NYAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NYAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NYAP1 shows lower tumor expression in KIRC, COAD, KICH, UCEC, BRCA and KIRP. The KIRC box plot shows higher NYAP1 RNA expression in normal versus tumor tissue (log2 FC = −0.990, t-test p < 0.001).
This table shows molecular features associated with NYAP1 in patient tissues and cancer cell lines. In patient samples, NYAP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NYAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
